- Record: found
- Abstract: not found
- Article: not found
Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial
Martin Schlumberger ,
Sophie Leboulleux ,
Bogdan Catargi ,
Desiree Deandreis ,
Slimane Zerdoud ,
Stephane Bardet ,
Daniela Rusu ,
Yann Godbert ,
Camille Buffet ,
Claire Schvartz ,
Pierre Vera ,
Olivier Morel ,
Danielle Benisvy ,
Claire Bournaud ,
Marie-Elisabeth Toubert ,
Antony Kelly ,
Ellen Benhamou ,
Isabelle Borget
August 2018
August 2018
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
In ESTIMABL1, a randomised phase 3 trial of radioactive iodine (131I) administration
after complete surgical resection in patients with low-risk thyroid cancer, 92% of
patients had complete thyroid ablation at 6-10 months, defined as a recombinant human
thyroid-stimulating hormone (rhTSH)-stimulated serum thyroglobulin concentration of
1 ng/mL or less and normal findings on neck ultrasonography. Equivalence was shown
between low-activity (1·1 GBq) and high-activity (3·7 GBq) radioactive iodine and
also between the use of rhTSH injections and thyroid hormone withdrawal. Here, we
report outcomes after 5 years of follow-up.